ClinicalTrials.gg

Program

HB0034

A development code.

Its studies are mostly in Psoriasis, led by Shanghai Huaota Biopharmaceutical.

Furthest: phase 3, since Jun 22, 20245 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Huaota Biopharmaceutical53 open or runningphase 3since Jun 22, 2024Sep 22, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2021First study: phase 1 study in HealthyFirst studyNCT05064345 · 56 enrolled · New Zealand
  2. Aug 22, 2022Phase 1 study in PsoriasisNCT05512598 · 9 enrolled · China
  3. Jan 21, 2024Phase 2 study in PsoriasisNCT06231381 · 33 planned · China
  4. Jun 22, 2024Phase 3 study in PsoriasisNCT06477536 · 33 planned · China
  5. Nov 29, 2024Phase 1 study in HealthyNCT06716151 · 60 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06716151Healthy · China1RecruitingNov 20, 202560
NCT06477536Psoriasis · China3RecruitingDec 30, 202533
NCT06231381Psoriasis · China2RecruitingFeb 13, 202533
NCT05512598Psoriasis · China1CompletedNov 15, 20239
NCT05064345Healthy · New Zealand1CompletedSep 1, 202256

How it is read

Names in the registry

  • “HB0034”, 5 entries

Codes read as this program: HB0034.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
HB0034 (Shanghai Huaota Biopharmaceutical): development program | ClinicalTrials.gg